US$76 million Series B financing to advance new target drugs for Alzheimer's disease Phase 2 June 14, 2018 Source: WuXi PharmaTech Recently, Cortexyme, headquartered in San Francisco, California, announced the completion of the B round of $76 million in financing. Cortexyme is a privately held clinical stage pharmaceutical company focused on drug development for the treatment of Alzheimer disease (AD) and other neurodegenerative diseases. Investors in this financing include Sequoia Capital, Vulcan Capital, Verily Life Sciences, EPIQ Capital Group, RSL Investments, Huizenga Capital, and one of the world's largest long-term mutual funds. Cortexyme's existing investors, such as Pfizer, Takeda Ventures, Lamond Family, Breakout Ventures and Dolby Family Ventures, also voted. AD is a common type of dementia, its harm can not be ignored, the number of patients worldwide is as high as 15 million, and the United States has 5.5 million. Due to the lack of effective treatment, the number of patients is expected to increase to approximately 75 million by 2030. Many companies are trying to develop therapeutic targets for neurodegenerative diseases, such as amyloid and Tau, but so far there has been no breakthrough. In the past decade or so, multiple drug developments have failed in clinical trials, and Pfizer has recently suspended drug development for such diseases. This makes finding new therapeutic targets an important task. ▲ Dr. Stephen Dominy (Source: Cortexyme official website) The target of the drug currently being developed by Cortexyme is an infectious pathogen with details that remain confidential. It has been found in human and animal model studies that the pathogen is associated with neurodegenerative and chronic inflammation. The pathogen is the company's co-founder, and Dr. Stephen Dominy, chief scientific officer, discovered a new target for AD treatment in the brains of AD patients. Cortexyme designed a first-in-class drug, COR388, a specific bacterial protease inhibitor against this pathogen. It is resistant to pathogens from other broad-spectrum antibiotics, thereby preventing bacterial toxicity from damage to the gods and preventing cognitive decline and disability. COR388 has completed Phase 1 clinical safety trials in animals and placebo, demonstrating its safety in the 20-70 age group, as well as good tissue distribution and pharmacokinetic properties when administered orally. The new financing will be used to advance phase 2 clinical effectiveness trials to complete proof of concept and will also be used to develop other derivative small molecule drugs. Mr. Michael Dixon, partner of Sequoia Capital, said: "The medical and social problems caused by AD are major challenges that humans have faced for decades. Obviously we need new treatment options. Cortexyme is trying to develop a new treatment to solve AD. This ill-health, the underlying cause of the disease, Sequoia is pleased to close the stage 1 clinical trial, ready to enter the post-test, this node and Cortexyme to work together to solve the disease affecting millions of patients around the world." ▲ Ms. Casey Lynch (Source: Cortexyme page) Cortexyme co-founder and CEO, Casey Lynch, said: “Cortexyme is pleased to have the support of some of the world's most successful investors, whether from the pharmaceutical industry or in other areas. In just four years, we The efficient drug development model has allowed us to move from seed funding to clinical phase 1. We are fully promoting the Phase 2 trial to bring new drugs to patients suffering from AD and similar diseases as soon as possible." We look forward to further positive results in the clinical trial of COR388. We also look forward to more new ideas and new concepts of AD drug therapy entering the clinical trial development stage in the future, and benefiting the majority of AD patients at an early date! Reference materials: [1] Cortexyme Completes $76 Million Series B Financing and Provides Update on Clinical Progress [2] Bay Area startup Cortexyme gains a $76M round to back a PhII Alzheimer's study, with a new target in their sights [3] E-Scape Bio A round of financing of $ 63 million, see the treatment of Alzheimer's disease! Steroids are a class of lipid soluble hormones. In the maintenance of life, regulating sexual function, body development, immune regulation, skin disease treatment and birth control has obvious effect. Steroid hormones are mainly used for: anti-inflammatory and anti-allergic; Treatment of male and female diseases and contraception; Improve metabolic function. Major side effects: more significant damage to the liver, and female masculinity. Long-term or a large number of use will appear acne, hairy, atrophic lines, purpura, osteoporosis, femoral head necrosis. steroids side effects,steroids bodybuilding,buy steroids,steroids benefits.steroids bodybuilding Shaanxi YXchuang Biotechnology Co., Ltd , https://www.peptide-nootropic.com
